Biogen Inc. on Wednesday published the full efficacy results from two late-stage studies of its Alzheimer’s disease drug Aduhelm in a lesser-known medical journal, nine months after U.S. regulators cleared the treatment.
Cambridge, Massachusetts-based Biogen had been under pressure to divulge the full details from the trials, which ultimately produced conflicting results after being halted early. One study suggested that the treatment, which removes a plaque called amyloid from the brain, could slow the progression of Alzheimer’s. The other did not. The mixed results led to intense debate about whether the drug would provide patients with much benefit.
The results published on Wednesday didn’t reveal any new information that is expected to substantially alter the controversy around the drug. The company also said on Wednesday that an extension study showed that after 2 1/2 years of treatment, patients continued to see a decline in key measures of disease pathology.
